RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
  • Regulatory NewsRegulatory News

    EMA Begins Review of Handling Errors Linked to Leuprorelin

    At the request of Germany’s BfArM, the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review of depot formulations of leuprorelin medicines because of reports of handling errors during preparation and administration that can cause some to receive insufficient amounts. EMA explains how depot formulations of leuprorelin medicines, which are better known by different brand names like Eligard, Lupron and Procren, release the...
  • Regulatory NewsRegulatory News

    EMA Begins Safety Review of MS Drug Lemtrada

    The European Medicines Agency (EMA) on Friday initiated a review of Sanofi’s multiple sclerosis (MS) drug Lemtrada (alemtuzumab) following new reports of immune-mediated conditions and problems with the heart and blood vessels of those taking the medicine, including deaths. “As a temporary measure while the review is ongoing, Lemtrada should only be started in adults with relapsing-remitting multiple sclerosis that is highly active despite treatment with at least two di...
  • Regulatory NewsRegulatory News

    European Regulatory Roundup: EU Stands Firm on Demand for UK to Pay for EMA’s Exit (7 December 2017)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. EU Stands Firm on Demand for UK to Pay for EMA’s London Exit The European Commission has reiterated its demand for the UK to cover the cost of the European Medicines Agency’s (EMA) withdrawal from London. That would mean the UK paying the €400 million ($470 million)-plus bill EMA will face as result of breaching its rental agreement. European officials first stated th...
  • Regulatory NewsRegulatory News

    EMA Restricts Use of Biogen MS Drug

    The European Medicines Agency (EMA) on Friday announced it is provisionally restricting the use of Biogen Idec’s multiple sclerosis (MS) medicine Zinbryta (daclizumab) to patients with highly active relapsing disease that have failed to respond to other drugs, and to patients with rapidly evolving relapsing disease who cannot be treated with other medicines.  In addition, EMA said, "patients with liver injury must not be given the medicine. Starting treatment with ...
  • Regulatory NewsRegulatory News

    European Regulatory Roundup: ENVI Urges EC to Exclude Healthcare From Regulation of Professions (15 June 2017)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. ENVI Urges Commission to Exclude Healthcare From Regulation of Professions A public health committee has urged the European Commission to exclude healthcare jobs from changes to the regulation of professions. The Committee on the Environment, Public Health and Food Safety (ENVI) is worried the proposed legislation is “too complex to implement” and involves “too much re...
  • Regulatory NewsRegulatory News

    EMA’s PRAC to Hold First Public Hearing on Use of Valproate Medicines

    The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) will hold its first public hearing on 26 September 2017 to discuss the safety of using valproate-containing medicines in the treatment of various conditions for women and girls who are pregnant or of childbearing age.  The public element of the meeting means EU citizens will be invited to share their experiences with these medicines, which are approved nationally in the EU to ...
  • Regulatory NewsRegulatory News

    European Regulatory Roundup: EMA Issues Increasing Number of GMP Non-Compliance Statements in India (11 May 2017)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. EU GMP Inspectors Issued Non-Compliance Statements to 11% of Indian Sites Visited in 2016 Authorities in the European Economic Area (EEA) issued non-compliance statements to 11% of the Indian drug manufacturing plants they inspected in 2016. The rate of non-compliance is far higher than the 1% recorded globally in 2016 and the 4-6% level seen in India in the three prev...
  • Regulatory NewsRegulatory News

    EMA Completes Postmarket Safety Review of Uptravi

    Less than two months after launching a safety review of Actelion Pharmaceuticals' pulmonary arterial hypertension (PAH) drug, Uptravi (salexipag), the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) says it did not find an increased risk of death associated with the drug. In February, EMA advised doctors to closely follow the approved prescribing information for Uptravi after learning of the deaths of five patients taking the drug i...
  • Regulatory NewsRegulatory News

    European Regulatory Roundup: EMA’s PRAC Seeks to Suspend Four Imaging Agents (16 March 2017)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. PRAC Asks to Suspend Authorizations of Four Imaging Agents After Reviewing Safety The Pharmacovigilance and Risk Assessment Committee (PRAC) has recommended the suspension of the marketing authorizations for four linear gadolinium contrast agents. PRAC put forward the proposal after finding “convincing evidence” accumulations of gadolinium are present in the brain many month...
  • Regulatory NewsRegulatory News

    EMA Reviews Safety of PAH Medicine Following 5 Deaths in France

    The European Medicines Agency (EMA) signaled Tuesday that doctors can continue to use Actelion Pharmaceuticals’ pulmonary arterial hypertension (PAH) medicine Uptravi (selexipag) while the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) evaluates its safety following the deaths of five patients taking the medicine in France. “Based on a preliminary review of available data, EMA advises that Uptravi may continue to be used, both in existing and new pat...
  • Regulatory NewsRegulatory News

    European Regulatory Roundup: EMA Offers Draft Proposal on Dissolution of Generics (19 May 2016)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. EMA Posts Draft Reflection Paper on Dissolution of Generic Oral Drugs The European Medicines Agency (EMA) has released a draft reflection paper about the dissolution specification of generic oral immediate release drugs. EMA has used the paper to propose a decision tree designed to counter doubts about the suitability of dissolution specifications and increase the tran...
  • Regulatory NewsRegulatory News

    European Regulatory Roundup: Germany Joins EU Medical Countermeasure Procurement Alliance (21 April 2016)

    Welcome to our European Regulatory Roundup, our weekly overview of the top EU regulatory news. PRAC Adopts Rules for Public Hearings on Safety Reviews Ahead of dry run in July The Pharmacovigilance Risk Assessment Committee (PRAC) has adopted rules of procedure for public hearings on safety reviews. PRAC, which could hold its first public hearing by the end of the year, is working on the initiative to give its members a way to gather the views of patients on safety is...